* NEOVACS *
1993 - IDF
Paris
www.neovacs.com Discovery, Immunology
Key words: Therapeutic vaccines, Cancer, Inflammatory diseases, Antibodies, Kinoids, Toxoids
Mission: to develop anti-cytokine and anti-protein viral regulation therapeutic vaccines to treat certain cancers and inflammatory diseases
Clients: Prescribers
contact@neovacs.com
Age: 19 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Managing Dir.-CEO: Fanneau de la Horie (Guy-Charles) [born 1959, Vet.D., MBA, ex-IDM, Biogen (President Europe), Schering-Plough]
Sc.Dir.-CSO: Grouard-Vogel (Géraldine) [Pharm.D., Ph.D. immunology, ex-Aventis Pasteur, Walter Reed Army Institute]
Pharm.Dir.: Fanget (Bernard) [ex-Flamel, Sanofi Pasteur]
Fin.Dir.-CFO:
BusDev: Whitehead (Piers) [Oxford, ex-VaxGen, Mercer Management Consulting]
Comm.Dir.: Hocdée-Leroy (Florence) [EM Lyon, ex-Rhône-Poulenc, KBC Securities, Grosvenor]
Financers (Hist.): Truffle Ventures, Europe Innovation, Debiopharm, Novartis, OTC Asset Management
note : at the end of December 2010, Novartis shares account for 26.6% | Turnover (M€) : 0.05 (2008), 1.4 (2006)
Total funding (M€) : n.a.
Last funding (M€) : 2.6
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .06 | Financing (no interest loan) : 1.5 M€, by OSEO Innovation to support Tracker (follow-up of 2008 deal) | DEBT | [18 years] |
| 2011 .04 | Financing (capital increase): 2.25 M€ by Debiopharm, Truffle Venture and OTC Asset Management [followed in June by 0.4 M€, dedicated to foreign shareholders) | PBO | [18 years] |
| 2010 .12 | Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis (end, with promising results) | CLIN | [17 years] |
| 2010 .04 | Listing on Alternext : 10 M€ (IPO) | PBO | [17 years] |
| 2009 .12 | Clinical trial (phase II) for TNFa-kinoid, a therapeutic vaccine in rheumatoid arthritis patients failing TNFa monoclonal antibody therapy (beginning) | CLIN | [16 years] |
| 2008 .11 | Clinical trial (phase I-II) for TNFa-kinoid, a therapeutic vaccine for the treatment of TNFa dependent auto-immune diseases in South-Africa (beginning) | CLIN | [15 years] |
| 2008 .10 | Financing (no interest loan) : 5.4 M€ (and 2.5 M€ grant), by OSEO Innovation to support Tracker, a theranostics project concerning rheumatoid arthritis from Neovacs (leader) and Biomedical Diagnostics | DEBT | [15 years] |
| 2007 .07 | Round-financing : 13.0 M€, by Novartis and previous shareholders | RFIN | [14 years] |
| 2006 .06 | Licensing-out to Debiopharm with capital sharing | LICOUT | [13 years] |
| 2006 .06 | Nomination : Guy Fanneau de la Horie, as CEO | ORGN | [13 years] |
| 2004 .10 | Round-financing : 1.5 M€, by Truffle Ventures and 1.2 M€, by Anvar | RFIN | [11 years] |
| 2003 .07 | Nomination : Alain Huriez, as CEO (still, as Director, Truffle Venture) | ORGN | [10 years] |
| 2003 .06 | Round-financing : 3.5 M€, by Truffle Ventures and Europe Innovation (reaching 51% of capital) | RFIN | [10 years] |
| 1999 .00 | Licensing-out of HIV therapeutic vaccine to Aventis Pasteur | LICOUT | [5 years] |
| 1998 .00 | Nomination : Jean-François Bensahel, as CEO | ORGN | [4 years] |
| 1993 .04 | Company founded by Daniel Zagury (immunologist), as a spin-off from Pierre et Marie Curie Paris University | ORGF | [0 year] | Actualisation / Updating: 23-Sep-2011 |
|
